BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 10942942)

  • 1. Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
    Ruano D; Diaz MA; Tutor O; Garcia-Sanchez F; Martinez P; Madero L
    Haematologica; 2000 Aug; 85(8):877-8. PubMed ID: 10942942
    [No Abstract]   [Full Text] [Related]  

  • 2. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
    Lauten M; Cario G; Asgedom G; Welte K; Schrappe M
    Haematologica; 2003 Nov; 88(11):1253-8. PubMed ID: 14607754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
    N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The treatment results in children diagnosed with non-Hodgkin's lymphomas and acute B-cell lymphoblastic leukemias treated by the BFM protocols. The report of the POGM (Pediatric Oncology Group of Madrid)].
    Vivanco Martínez JL; López Pérez J; Melero Moreno C; Torres Valdivieso MJ; Palacios López ME; Contra Gómez T; Martín Ramos N; Bernacer Borja M; Gil López C; Valverde Moreno F
    An Esp Pediatr; 1998 Dec; 49(6):603-8. PubMed ID: 9972623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No advantage of a rotational continuation phase in acute lymphoblastic leukemia in childhood treated with a BFM back-bone therapy.
    Felice MS; Rossi JG; Gallego MS; Alfaro EM; Zubizarreta PA; Fraquelli LE; Alonso CN; Guitter MR; Scopinaro MJ
    Pediatr Blood Cancer; 2011 Jul; 57(1):47-55. PubMed ID: 21394895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of the reaction to steroids in the treatment of acute lymphoblastic leukemia in children].
    Urasiński T; Peregud-Pogorzelski J; Bartoszewicz L
    Pol Tyg Lek; 1992 Apr 20-27; 47(16-17):360-2. PubMed ID: 1437754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of reinduction chemotherapy in bone marrow relapse of childhood acute lymphoblastic leukemia].
    Sato Y; Ito R; Saito T; Suto Y; Tateoka N; Onodera N; Ikeda Y; Ito E; Miyano T; Tachibana N
    Rinsho Ketsueki; 1989 Nov; 30(11):1923-30. PubMed ID: 2607611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
    Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
    Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
    Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen.
    Kudva GC; Chandy M; Dennison D; Srivastava A; Bhushan V
    Indian J Cancer; 1994 Mar; 31(1):1-7. PubMed ID: 8063329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
    Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
    Galimberti S; Marasca R; Caracciolo F; Fazzi R; Papineschi F; Benedetti E; Guerrini F; Morabito F; Oliva E; Di Renzo N; Federico M; Petrini M; Torelli G;
    Bone Marrow Transplant; 2002 Apr; 29(7):581-7. PubMed ID: 11979307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
    Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
    Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 expression and poor prognosis in childhood acute lymphoblastic leukemia.
    Hecker S; Sauerbrey A; Volm M
    Anticancer Res; 1994; 14(6B):2759-61. PubMed ID: 7872714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intact T-cell regenerative capacity in childhood acute lymphoblastic leukemia after remission induction therapy.
    Moritz B; Eder J; Meister B; Heitger A
    Med Pediatr Oncol; 2001 Feb; 36(2):283-9. PubMed ID: 11452936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [DNA index and proliferative activity of blastic cells in childhood ALL].
    Peregud-Pogorzelski J; Fydryk J; Krygier-Stojałowska A; Urasiński T; Kamieńska E
    Acta Haematol Pol; 1995; 26(1):73-9. PubMed ID: 7747566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.